Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Aims
3. Global initiative for asthma (GINA)
4. Beta2-agonists in asthma
5. Duration of action of inhaled beta2-agonists
6. LABA monotherapy in asthma
7. Specific label changes for LABAs
8. Glucocorticoids in asthma
9. Complementary effects of LABAs and ICS
10. Combination therapy in asthma
11. Combination inhalers of LABA and ICS
12. Scientific rationale for combination therapy
13. Mechanisms of glucocorticoid action
14. Effects of beta2-agonists on CS effects
15. Formoterol enhances GR translocation in vivo
16. LABAs increase anti-inflammatory effects of CS
17. Effect of ICS on GR nuclear localisation in vivo
18. Salmeterol enhances GR translocation
19. Effect of beta2-agonists on GR activation
20. Effects of CSs on beta2-agonist effects
21. Effects of corticosteroids on beta2-receptors
22. Corticosteroids enhance LABA bronchodilation
23. Combination better than separate components
24. Conclusions
25. Thank you

Topics Covered

• Asthma treatment guidelines
• Pharmacology of inhaled corticosteroids and long-acting beta agonists
• Clinical evidence for combination therapy in asthma
• Molecular interactions between inhaled corticosteroids and long-acting beta agonists

Links

Series:

• Advances in Asthma

Categories:

• Clinical Practice
• Immunology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on February 19, 2012

Financial Disclosures

• Dr. Omar S. Usmani, Speaker’s bureau: Takeda, Chiesi ; Grant/Research Support (Principal Investigator): Chiesi, GSK, Astra Zeneca, Takeda.